Price Chart

Profile

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
URL http://www.abbvieinvestor.com
Investor Relations URL https://investors.abbvie.com
HQ State/Province Illinois
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Value
Next Earnings Release Apr. 26, 2024 (est.)
Last Earnings Release Feb. 02, 2024
Next Ex-Dividend Date Apr. 12, 2024
Last Ex-Dividend Date Jan. 12, 2024

Profile

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
URL http://www.abbvieinvestor.com
Investor Relations URL https://investors.abbvie.com
HQ State/Province Illinois
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Value
Next Earnings Release Apr. 26, 2024 (est.)
Last Earnings Release Feb. 02, 2024
Next Ex-Dividend Date Apr. 12, 2024
Last Ex-Dividend Date Jan. 12, 2024